More Articles


What Can Pharma Expect in 2019?

The eyeforpharm..., (Jan 7, 2019)

Our look at the biggest trends hitting the industry over the coming 12 months
Access and Evidence

Gold Standard: Standardizing RWD

Nicola Davies, (Jan 4, 2019)

If real-world data is to deliver on its promise, it needs to be standardized

Releasing Pharma’s Potential

Adam Chapman, (Jan 3, 2019)

The industry has a new frontier in its sights. LEO Pharma’s CEO provides us with a blueprint to get there.
Access and Evidence

Blockchain: Solution Or Snake Oil?

Ross Davies, (Dec 19, 2018)

The potential of blockchain to better manage RWE and access makes it an exciting prospect. However, pharma first needs to get its head around the practical application.
Patients and Medical

Has Medical Affairs Become A Victim Of Its Own Success?

Ross Davies, (Dec 18, 2018)

As medical affairs mushrooms, new skills and capabilities are urgently needed.

Pills? What pills?

Adam Chapman, (Dec 13, 2018)

Three ‘Without The Pill’ Digital Therapeutics You Need To Know About
Patients and Medical

Growing Pains

Hugh Gosling, (Dec 12, 2018)

How companies are scaling up their patient-centric efforts
Access and Evidence

VBCs: Are They Working?

Adam Chapman, (Dec 12, 2018)

Are value-based contracts actually improving patient access to new medicines?

The Bigger Picture

Adam Chapman, (Dec 11, 2018)

Merck’s Chief Medical Officer reflects on his career thus far and weighs in on the industry’s biggest opportunities and challenges.
Patients and Medical

Made to Measure

Hugh Gosling, (Dec 11, 2018)

After many years of patient-centric efforts, pharma is finally starting to measure its impact